The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
NF-κB addiction and its role in cancer: ‘one size does not fit all’
Open accessAbstract
Activation of nuclear factor (NF)-κB, one of the most investigated transcription factors, has been found to control multiple cellular processes in cancer including inflammation, transformation, proliferation, angiogenesis, invasion, metastasis, chemoresistance and radioresistance. NF-κB is constitutively active in most tumor cells, and its suppression inhibits the growth of tumor cells, leading to the concept of ‘NF-κB addiction’ in cancer cells. Why NF-κB is constitutively and persistently active in cancer cells is not fully understood, but multiple mechanisms have been delineated including agents that activate NF-κB (such as viruses, viral proteins, bacteria and cytokines), signaling intermediates (such as mutant receptors, overexpression of kinases, mutant oncoproteins, degradation of IκBα, histone deacetylase, overexpression of transglutaminase and iNOS) and cross talk between NF-κB and other transcription factors (such as STAT3, HIF-1α, AP1, SP, p53, PPARγ, β-catenin, AR, GR and ER). As NF-κB is ‘pre-active’ in cancer cells through unrelated mechanisms, classic inhibitors of NF-κB (for example, bortezomib) are unlikely to mediate their anticancer effects through suppression of NF-κB. This review discusses multiple mechanisms of NF-κB activation and their regulation by multitargeted agents in contrast to monotargeted agents, thus ‘one size does not fit all’ cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Anand, P., Kunnumakkara, A. B., Harikumar, K. B., Ahn, K. S., Badmaev, V., & Aggarwal, B. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1902 · Cited by 69
Self-citationRetractedInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…pancreatic and brain cancers have revealed that cancer genomes are highly complex (Bignell et al., 2010; Ding et al., 2010; Pleasance et al., 2010a), with a range of 48–101 somatic alterations in each tumor, depending on the cancer type (Jones et al., 2008; Parsons et al., 2008; Bell, 2010).”
BackgroundCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 2×
“Mammalian NF-kB is a family of transcription factors that includes five members: RelA/p65, c-Rel, RelB, NF-kB1 (p50) and NF-kB2 (p52) (Ghosh and Karin, 2002; Vallabhapurapu and Karin, 2009).”
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 2×
“…addiction) It has become increasingly clear that besides having a role in regulating adaptive immune response, NF-kB signaling also has a critical role in cancer development and progression (Aggarwal, 2004; Basseres and Baldwin, 2006; Karin, 2006; Mantovani et al., 2008; Prasad et al., 2010).”
Background
Cited by
Liu, B., Sun, L., Liu, Q., Gong, C., Yao, Y., Lv, X., Lin, L., Yao, H., Su, F., Li, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.004 · Cited by 908
C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
Understanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects
Bolton, J. L., & Dunlap, T. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00256 · Cited by 522
The Multifaceted Role of Curcumin in Cancer Prevention and Treatment
Shanmugam, M., Rane, G., Kanchi, M., Arfuso, F., Chinnathambi, A., Zayed, M., Alharbi, S., Tan, B., Kumar, A., & Sethi, G. (2015) · Molecules · doi:10.3390/molecules20022728 · Cited by 510
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
ER Stress Activates NF-κB by Integrating Functions of Basal IKK Activity, IRE1 and PERK
Tam, A. B., Mercado, E. L., Hoffmann, A., & Niwa, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045078 · Cited by 347
Visceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice
Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.064 · Cited by 292
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
The role of Nuclear Factor-kappa B signaling in human cervical cancer
Tilborghs, S., Corthouts, J., Verhoeven, Y., Arias, D., Rolfo, C., Trinh, X. B., & van Dam, P. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.001 · Cited by 269
Emerging avenues linking inflammation and cancer
Kundu, J. K., & Surh, Y.-J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.035 · Cited by 264
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., & Chen, L.-F. (2014) · Oncogene · doi:10.1038/onc.2013.179 · Cited by 259
Cancer cell signaling pathways targeted by spice-derived nutraceuticals
Sung, B., Prasad, S., Yadav, V. R., & Aggarwal, B. B. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630551 · Cited by 204
Self-citationCancer Chemoprevention and Nutri-Epigenetics: State of the Art and Future Challenges
Gerhauser, C. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_360 · Cited by 194
Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140
Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121
Fahey, J. M., Stancill, J. S., Smith, B. C., & Girotti, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000443 · Cited by 59
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2834-8 · Cited by 56
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
Breuer, R., Becker, M. S., Brechmann, M., Mock, T., Arnold, R., & Krammer, P. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.533547 · Cited by 40
Metadata
- Authors
- Chaturvedi, M. M., Sung, B., Yadav, V. R., Kannappan, R., & Aggarwal, B. B.
- Venue
- Oncogene
- Published
- 2010-12-20
- Volume
- 30
- Issue
- 14
- Pages
- 1615-1630
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2038713860
- Cited by
- 473
- References
- 230
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.